Get to know our clinical trials

Randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

Imagen del Dr. Juan Pablo de Torres. Especialista en Neumología de la Clínica Universidad de Navarra. El Dr. Pablo de Torres se dedica preferencialmente al estudio y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica, el enfisema y su relación con el cáncer de pulmón.
Dr. Juan Pablo de Torres Tajes [SP] Curriculum
Codirector Pneumology Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEREKITUG (UPB-101) IN PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
  • Code EudraCT: 2025-520488-42-00
  • Protocol number: UPB-CP-06
  • Promoter: UPSTREAM INC
  • Molecule/Drug: UPB-101

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION